China Pharma Holdings (CPHI) Share-based Compensation (2010 - 2026)

China Pharma Holdings (CPHI) has reported Share-based Compensation for 12 consecutive years, with $15.0 million the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation changed N/A year-over-year to $15.0 million; the trailing twelve-month figure through Jun 2026 stood at $32.8 million (changed N/A YoY), and the FY2025 full-year result was $17.9 million, up 384.88% from the prior year.
• Share-based Compensation declined to $15.0 million in Q1 2026 per CPHI's latest filing, from $15.5 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $15.5 million in Q4 2025 and bottomed at -$410000.0 in Q4 2023.
• Historically, Share-based Compensation has averaged $3.1 million across 5 years, with a median of $828726.0 in 2022.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation soared 1212.08% in 2022, then plunged 140.7% in 2023.
• Over 5 years, Share-based Compensation stood at $1.0 million in 2022, then slumped by 140.7% to -$410000.0 in 2023, then surged by 668.29% to $2.3 million in 2024, then soared by 563.95% to $15.5 million in 2025, then declined by 3.08% to $15.0 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $15.0 million, $15.5 million, and $2.3 million for Q1 2026, Q4 2025, and Q4 2024 respectively.